Recurrent miscarriage syndrome and infertility caused by blood coagulation protein/platelet defects

Hematological Complications in Obstetrics, Pregnancy, and Gynecology

Volumn , Issue , 2006, Pages 55-74

  Bick, Rodger L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38349040648     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511526978.003     Document Type: Chapter

References (82)

1. Bick, R. L., Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects. Hematology Oncology Clin. North America, 14: 1117, 2000.
2. Bick, R. L., Laughlin, H. R., Cohen, B., et al. Fetal wastage syndrome due to blood protein/platelet defects: results of prevalence studies and treatment outcome with low-dose heparin and low-dose aspirin. Clin. Appl. Thrombosis Hemostasis, 1: 286, 1995.
3. Duckert, F. The fibrin stabilizing factor, Factor XIII. Blut, 26: 177, 1973.
4. Dossenbach-Glaninger, A., van Trotsenburg, M., Dossenbach, Oberkanins, C., et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin. Chem., 49: 1081, 2003.
5. Muszbek, I. A. Coagulation factor deficiencies and pregnancy loss. Sem. Thromb. Hemost., 29: 171, 2003.
6. Kumar, M. and Mehta, P. Congenital coagulopathies and pregnancy: report of four pregnancies in a Factor X-deficient woman. Am. J. Hematol., 46: 241, 1994.
7. Valnicek, S., Vacl, J., Mrazova, M., et al. Hemotherapeutic safeguarding of induced abortion in inborn proconvertin insufficiency (hemagglutination Factor VII) using exchange plasmapheresis. Zentralblatt fur Gynakologie, 94: 931, 1972.
8. Nelson, D. B., Ness, R. B., Grisso, J. A. and Cushman, M. Influence of hemostatic factors on spontaneous abortion Am. J. Perinatol., 4: 195, 2001.
9. Slunsky, R. Personal experiences with the antifibrinolytic PAMBA in obstetrics and gynecology. Zentralblatt für Gynakologie, 92: 364, 1970.
10. Owen, C. A., Henriksen, R. A., McDuffie, F. C., et al. Prothrombin quick: a newly identified dysprothrombinemia Mayo Clinic Proceedings, 53: 29, 1978.
11. Pauer, H. U., Burfeind, P., Kostering, H., et al. Factor XII deficiency is strongly associated with primary recurrent abortions. Fertil Steril. Sep., 80: 590, 2003.
12. Jones, D. W., Gallimore, M. J. and Winter, M. Antibodies to factor XII: a possible predictive marker for recurrent foetal loss. Immunobiology, 207: 43, 2003.
13. Sugi, T. and Makino, T. Antiphospholipid antibodies and kininogens in pathologic pregnancies: a review. Am. J. Reprod. Immunol., 47: 283, 2002.
14. Iinuma, Y., Sugiura-Ogasawara, M., Makino, A., et al. Coagulation factor XII activity, but not an associated common genetic polymorphism (46C/T), is linked to recurrent miscarriage. Fertil. Steril., 77: 353-6, 2002.
15. Yamada, H., Kato, E. H., Ebina, Y., et al. Factor XII deficiency in women with recurrent miscarriage. Gynecol. Obstet. Invest., 49: 80, 2000.
16. Evron, S., Anteby, S. O., Brzezinsky, A., et al. Congenital afibrinogenemia and recurrent early abortion. European J. Obstet. Gynecol. Reproductive Biol., 19: 307, 1985.
17. Mammen, E. F. Congenital abnormalities of the fibrinogen molecule. Seminars Thrombosis Hemostasis, 1: 184, 1974.
18. Bick, R. L., Baker, W. F. Antiphospholipid syndrome and thrombosis. Seminars Thrombosis Hemostasis, 25: 333, 1999.
19. Bick, R. L. The antiphospholipid thrombosis syndromes: a common mutlidisciplinary medical problem. Clin. Appl. Thrombosis Hemostasis, 3: 270, 1997.
20. Scott, J. R., Rote, N. S. and Branch, D. W. Immunological aspects of recurrent abortion and fetal death. Obstet. Gynecol., 70: 645, 1987.
21. Schved, J. F., Gris, J. C., Neveu, S., et al. Factor XII congenital deficiency and early spontaneous abortion. Fertility and Sterility, 52: 335, 1989.
22. Klein, M., Rosen, A., Kyrle, P., et al. Obstetrical management of dysfibrinogenemia with increased thrombophilia. Geburtshilfe und Frauenheilkunde, 52: 442, 1992.
23. Barkagan, Z. S. and Belykh, S. I. Protein C deficiency and the multi-thrombotic syndrome associated with pregnancy and abortion. Gematologia I Transfuziologiia, 37: 35, 1992.
24. Hellgren, M., Tengborn, L. and Abildgaard, U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecologic and Obstetric Investigation, 14: 127, 1982.
25. Simioni, P., Lazzaro, A. R., Coser, E., et al. Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate cohorts. Blood Coagulation and Fibrinolysis, 1: 351, 1990.
26. Satoh, A., Suzuki, K., Takayama, E., et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J. Rheum., 26: 1715, 1999.
27. Gris, J., Neveu, S., Mares, P., et al. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J. Lab. Clin. Med., 125:606, 1993.
28. Glueck, C. J., Wang, P., Fontaine, R. N., et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism: Clinical & Experimental, 48: 1589, 1999.
29. Khamashta, M. A. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus, 7(Suppl. 2): S162-5, 1998.
30. Amengual, O., Atsumi, T., Khamashta, M. A., et al. Advances in antiphospholipid (Hughes’) syndrome. Annals of the Academy of Medicine, Singapore, 27: 61, 1998.
31. Bick, R. L. Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and managment. International J. Hematology, 65: 193, 1997.
32. Bick, R. L., Baker, W. F. The Antiphospholipid and Thrombosis Syndromes. Medical Clinics North America, 78: 667, 1994.
33. Bick, R. L., Arun, B., Frenkel, E. P. Antiphospholipid thrombosis syndromes. Haemostasis, 29: 100, 1999.
34. Festin, M. R., Limson, G. M., Maruo, T. Autoimmune causes of recurrent pregnancy loss. Kobe Journal of Medical Sciences, 43: 143, 1997.
35. Roussev, R. G., Kaider, B. D., Price, D. E., et al. Laboratory evaluation of women experiencing reproductive failure. Am. J. Reproductive Immunology (Copenhagen), 35: 415, 1996.
36. Oshiro, B. T., Silver, R. M., Scott, J. R., et al. Antiphospholipid antibodies and fetal death. Obstetrics & Gynecology, 87: 489, 1996.
37. Granger, K. A. and Farquharson, R. G. Obstetric outcome in antiphospholipid syndrome. Lupus, 6: 509, 1997.
38. Borrelli, A. L., Brillante, M., Borzacchiello, C., et al. Hemocoagulative pathology and immunological recurrent abortion. Clinical & Experimental Obstetrics & Gynecology, 24: 39, 1997.
39. Hellan, M., Kuhnel, E., Speiser, W., et al. Familial lupus anticoagulant: a case report and review of the literature. Blood Coagulation & Fibrinolysis, 9: 195, 1998.
40. Ogasawara, M., Aoki, K., Matsuura, E., et al. Anti beta-2-glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance. Lupus, 5: 587, 1996.
41. Zangari, M., Lockwood, C. J., Scher, J., et al. Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies. Thromb. Res., 85: 177, 1997.
42. Aznar, J. Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion. Haematologica, 84: 80, 1999.
43. Aznar, J., Villa, P., Espana, F., et al. Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J. Lab. & Clin. Med., 130: 202, 1997.
44. Schultz, D. R. Antiphospholipid antibodies: basic immunology and assays. Seminars in Arthritis & Rheumatism, 26: 724, 1997.
45. Amengual, O., Atsumi, T., Khamashta, M. A., et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombosis & Haemostasis, 79: 276, 1998.
46. Martini, A. and Ravelli, A. The clinical significance of antiphospholipid antibodies. Annals of Medicine, 29: 159, 1997.
47. Bussen, S. S. and Steck, T. Thyroid antibodies and their relation to antithrombin antibodies, anticardiolipin antibodies and lupus anticoagulant in women with recurrent spontaneous abortions (antithyroid, anticardiolipin and antithrombin autoantibodies and lupus anticoagulant in habitual aborters). European J. Obs. Gyn. Repro. Biol., 74: 139, 1997.
48. Rand, J. H. and Wu, X. X. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thrombosis & Haemostasis, 82: 649, 1999.
49. Rand, J.H., Wu, X. X., Andree, H.A., et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood, 92: 1652, 1998.
50. Rauch, J. Lupus anticoagulant antibodies: recognition of phospholipid-binding protein complexes. Lupus, 7(Suppl. 2): S29, 1998.
51. Rote, N. S., Vogt, E., DeVere, G., et al. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am. J. Repro. Immunol. (Copenhagen), 39: 125, 1998.
52. Vogt, E., Ng, A. K. and Rote, N. S. Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Am. J. Obs. Gyn., 177: 964, 1997.
53. Lakasing, L., Campa, J. S., Poston, R., et al. Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome. Am. J. Obs. Gyn., 181: 180, 1999.
54. Siaka, C., Lambert, M., Caron, C., et al. Low prevalence of anti-annexin V antibodies in antiphospholipid syndrome with fetal loss. Revue de Medecine Interne, 20: 762, 1999.
55. Kaburaki, J., Kuwana, M., Yamamoto, M., et al. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am. J. Hematol., 54: 209, 1997.
56. Eschwege, V., Peynaud-Debayle, E., Wolf, M., et al. Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis. Blood Coagulation & Fibrinolysis, 9: 429, 1998.
57. Silver, R. M., Pierangeli, S. S., Edwin, S. S., et al. Pathogenic antibodies in women with obstetric features of antiphospholipid syndrome who have negative test results for lupus anticoagulant and anticardiolipin antibodies. Am. J. Obs. Gyn., 176: 628, 1997.
58. Branch, D. W., Silver, R., Pierangeli, S., et al. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obs. Gyn., 89: 549, 1997.
59. Gris, J. C., Ripart-Neveu, S., Maugard, C., et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thrombosis & Haemostasis, 77: 1096, 1997.
60. Tal, J., Schliamser, L. M., Leibovitz, Z., et al. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Human Reproduction, 14: 1624, 1999.
61. Kutteh, W. H., Park, V. M. and Deitcher, S. R. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertility & Sterility., 71: 1048, 1998.
62. Dhalback, B. Activated Protein C resistence and thrombosis: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Seminars Thrombosis Hemostasis, 25: 273, 1999.
63. Brenner, B., Mandel, H., Lanir, N., et al. Activated Protein C resistance can be associated with recurrent fetal loss. Brit. J. Haematology, 97: 551, 1997.
64. Bokarewa, M. I., Bremme, K., Blomback, M. Arg 506-Gln mutation in factor V and risk of thrombosis during pregnancy. Brit. J. Haematology, 92: 473, 1996.
65. Rai, R., Regan, L., Hadley, E., et al. Second-trimester pregnancy loss is associated with activated C resistance. Brit. J. Haematology, 92: 489, 1996.
66. Grandone, E., Margaglione, M., Colaizzo, D., et al. Factor V Leiden mutation is associated with repeated and recurrent unexplained fetal losses. Thromb. Haemostasis, 77: 822, 1997.
67. Ridker, P. M., Miletich, J. P., Buring, J. E., et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann. Internal Medicine, 128: 1000, 1998.
68. Poort, S., Rosendaal, F., Reitsma, P., et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis Blood, 88: 3698, 1996.
69. Brenner, B., Sarig, G., Weiner, Z., et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thrombosis & Haemostasis, 82: 6, 1999.
70. Toschi, V., Motta, A., Costelli, C., et al. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause Stroke, 29: 1759, 1998.
71. Sher, G., Feinman, M., Zouves, C., et al. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Human Reproduction, 9: 2278, 1994.
72. Rosove, M. H., Tabsh, K., Wasserstrum, N., et al. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstetrics Gynecology, 75: 630, 1990.
73. Brown, H. L. Antiphospholipid antibodies and recurrent pregnancy loss. Clinical Obstetrics Gynecology, 34: 17, 1991.
74. Perino, A., Barba, G., Cimino, C., et al. Immunological problems in the recurrent abortion syndrome. Acta Eurtopaea Fertilitatis, 20: 199, 1989.
75. Many, A., Pauzner, R., Carp, H., et al. Treatment of patients with antiphospholipid antibodies during pregnancy. American J. Reproductive Immunology, 28: 216, 1992.
76. Lubbe, W. F. and Liggins, G. C. Role of lupus anticoagulant and autoimmunity in recurrent fetal loss. Seminars Reproductive Endocrinology, 6: 181, 1988.
77. Lin, Q. Investigation of the association between autoantibodies and recurrent abortions. Chinese J. Obstetrics Gynecology, 28: 674, 1993.
78. Cowchuck, F. S., Reece, E. A., Balaban, D., et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. American J. Obstetrics Gynecology, 166: 1318, 1992.
79. Landy, H. J., Kessler, C., Kelly, W. K., et al. Obstetric performance in patients with the lupus anticoagulant and/or anticardiolipin antibodies. American J. Perinatology, 9: 146, 1992.
80. Semprini, A. E., Vucetich, A., Garbo, S., et al. Effect of prednisone and heparin treatment in 14 patients with poor reproductive efficiency related to lupus anticoagulant. Fetal Therapy, 4(Suppl. 1): 73, 1989.
81. Kutteh, W. H. Heparin plus aspirin (Hep + ASA) is superior to aspirin alone (ASA) for the treatment of recurrent pregnancy loss (RPL) associated with antiphospholipid antibodies (APA). Proceedings: American College Obstetricians & Gynecologists, 1994 (abstract).
82. Parke, A. The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses. IVIG Therapy Today. Ballow, M., ed. Totowa, N. J., Humana Press, Inc., 1992, p. 105.